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Abstract 26	
Background 27	
 Human gut bacteria can synthesize proteinogenic amino acids and produce a range of 28	
metabolites via protein fermentation, some known to exert beneficial or harmful 29	
physiological effects on the host. However, the effects of the type and amount of dietary 30	
protein consumed on these metabolic processes, as well as the effects of the microbiota-31	
derived amino acids and related metabolites on the host health are still predominantly 32	
unknown.  33	
Scope and Approach 34	
 This review provides an up-to-date description of the dominant pathways/genes 35	
involved in amino acid metabolism in gut bacteria, and provides an inventory of 36	
metabolic intermediates derived from bacterial protein fermentation that may affect 37	
human health. Advances in understanding bacterial protein fermentation pathways and 38	
metabolites generated at a global level via the implementation of ‘omics’ technologies 39	
are reviewed. Finally, the impact of dietary protein intake and high-protein diets on 40	
human health is discussed. 41	
Key Findings and Conclusions 42	
 The intestinal microbiota is able to synthesize amino acids, but the net result of 43	
amino acid production and utilization, according to dietary patterns still needs to be 44	
determined. The amount of ingested dietary protein appears to modify both the diversity 45	
and composition of the intestinal microbiota as well as the luminal environment of the 46	
intestinal epithelium and peripheral tissues. The understanding of the consequences of 47	
such changes on the host physiology and pathophysiology is still in an early stage but 48	
major progress is expected in the near future with the investigation of host-microbe 49	
omics profiles from well-controlled human intervention studies. 50	
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1.  Introduction 76	
 The dietary protein consumption level in humans is vastly different according to food 77	
availability and cultural dietary habits (Wu, et al., 2014). Although insufficient protein 78	
consumption remains a persistent problem in the developing world, the average daily 79	
protein intake in countries from Western Europe and the United States of America is 80	
generally higher than the recommended dietary intake of 0.83 g protein•kg-1•day-1 for 81	
adults (EFSA Panel on Dietetic Products, 2012; Rand, Pellett, & Young, 2003). In 82	
individuals consuming a high-protein (HP) diet as a way to reduce their body weight, 83	
the protein consumption generally consists of approximately two to three times the 84	
recommended dietary intake; and can even represent five times this latter value (Pesta & 85	
Samuel, 2014).  Such diets have been shown to increase satiety, modify lipid 86	
metabolism, and facilitate short- and medium-term weight reduction (Westerterp-87	
Plantenga, Nieuwenhuizen, Tome, Soenen, & Westerterp, 2009). Although a reduction 88	
of body weight in overweight and obese individuals is obviously associated with 89	
favorable outcomes in terms of health (Papillard-Marechal, et al., 2012), such dietary 90	
modification are also associated with potentially deleterious effects in both healthy 91	
situations in the long-term and in some pathological situations, notably in kidney 92	
diseases (Juraschek, Appel, Anderson, & Miller, 2013) and in inflammatory bowel 93	
diseases (Jowett, et al., 2004).  94	
 Besides host physiological factors, recent evidence demonstrates that human gut 95	
microbiota in the small and large intestine also plays a role in host dietary protein 96	
metabolism. The interplay between host and gut microbial metabolism is complex, with 97	
microbes utilizing and even competing for dietary and endogenous proteins. 98	
Fermentation of amino acids by gut bacteria produces metabolites that can affect host 99	
protein/amino acid uptake (transport) and metabolism, as well as affect host cell 100	
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physiology (Davila, et al., 2013). Bacteria can also synthesize amino acids, which can 101	
be provided to the host (Metges, 2000). However, the net result of amino acid synthesis 102	
and degradation remains largely to be determined along with the role of the gut 103	
microbiota for the management of whole body nitrogen metabolism (Neis, Dejong, & 104	
Rensen, 2015). Such knowledge is important since it will yield information regarding 105	
the role of the microbiota in the utilization of amino acids from dietary origin in 106	
different physiological and pathological situations, as well as the role of the microbiota 107	
in the production of metabolites that could be available for the host and impact host 108	
metabolism and other physiological functions. 109	
 Despite the relatively rapid transit of the luminal content in the small intestine, part 110	
of the amino acid pool released from proteins through the action of pancreatic enzymes 111	
can be used by the host enterocytes (Davila, et al., 2013) as well as by the small 112	
intestinal microbiota (Dai, Zhang, Wu, & Zhu, 2010). Protein digestion in the 113	
mammalian digestive tract is a very efficient process, being generally equal to or even 114	
higher than 90% (Bos, et al., 2005). In the large intestine, where the microbiota 115	
concentration is much higher and the transit time is longer than in the small intestine, 116	
the remaining protein is broken down to peptides and amino acids via extracellular 117	
bacterial proteases and peptidases (Macfarlane, Cummings, & Allison, 1986). In 118	
contrast to the small intestine, however, the amino acids generated cannot be absorbed 119	
to any significant extent by the large intestine epithelium, except during the neonatal 120	
period in mammals (Darragh, Cranwell, & Moughan, 1994). Gut bacterial fermentation 121	
of amino acids thus results in an accumulation of various metabolic end-products in the 122	
luminal content, some of these metabolites being largely absorbed through the large 123	
intestinal epithelial cells, while others are released in feces in large amounts (Davila, et 124	
al., 2013). Several bacterial metabolites have also been shown to be active on colonic 125	
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epithelial cells, which, as detailed below, depending on their luminal concentrations, 126	
can exert beneficial or deleterious effects. 127	
 Bacterial metabolites which are not fully metabolized/detoxified by the colonic 128	
epithelial cells during their transcellular journey from the intestinal lumen to the 129	
bloodstream may reach the liver through the portal vein and then peripheral tissues 130	
where they can exert some biological effects, notably on kidney functions.  131	
 Investigations into the effects of microbially-derived metabolites on human health 132	
and the interaction of the microbiota with the human host have previously been limited 133	
due to the complexity of interactions between these two systems. The rapid advance of  134	
‘omics’ technologies are beginning to expand our understanding of the relationships 135	
between the human host and gut microbiota by allowing a global analysis of the flow of 136	
host- and microbially-produced metabolites and genes involved in specific biochemical 137	
pathways (Qin, et al., 2010; Sridharan, et al., 2014). A thorough characterization and 138	
understanding of the bacterial pathways involved in amino acid metabolism and their 139	
derivatives is required for precise interpretation and prediction of dietary protein effects 140	
on the host health. Currently, a comprehensive review of those bacterial genes and 141	
metabolic routes is lacking. 142	
 This review merges up-to-date genomic information regarding amino acid-related 143	
metabolism in gut bacteria with their potential effects on human health. A description of 144	
the dominant pathways for bacterial amino acid biosynthesis as well as for amino acid 145	
degradation into metabolites that may play different roles in human health is provided. 146	
Moreover, information on the enzymes and homologous genes involved in these 147	
pathways as deduced from the KEGG database (Kanehisa, et al., 2014) is given. We 148	
then discuss the recent advances in understanding the effects of different dietary 149	
strategies (i.e. high-fat diet and HP diet) on the human gut microbiome and its role in 150	
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protein/amino acid metabolism based on metagenomic and metabolomic studies. 151	
Finally, we analyzed how this metabolic activity, notably in terms of bacterial 152	
metabolite production, may be responsible for the effects of dietary protein intake levels 153	
on health-related outcomes in both physiological and pathological situations as well as 154	
underline research areas that need new developments.   155	
   156	
 157	
2.  Bacterial synthesis of amino acids 158	
 The effects of de novo production of amino acids by microbes on whole-body fluxes 159	
and human health are still not clearly understood. Bacterial production of amino acids 160	
that are accessible to the host may be useful to compensate indispensable amino acid 161	
deficiency in low quality protein diets. However, bacterially-produced amino acids 162	
could also have detrimental consequences in conditions such as insulin resistance in 163	
type 2 diabetes where systemic concentrations of amino acids such as aromatic and 164	
branched-chain amino acids are elevated (Neis, et al., 2015). A deeper understanding of 165	
the effects of microbially-produced amino acids on host health is warranted, as well as a 166	
revision of the biosynthetic pathways of amino acids in bacteria which is provided here. 167	
 168	
2.1. Pathways/genes involved in de novo biosynthesis of amino acids 169	
 Due to the high metabolic cost of synthesizing amino acids, the carbon backbone of 170	
all amino acids originates from common metabolic intermediates involved in processes 171	
such as the tricarboxylic acid cycle, the pentose phosphate pathway and glycolysis 172	
(Berg, Tymoczko, & Stryer, 2002). Among these intermediates, α-ketoglutarate plays a 173	
central role in amino acid biosynthesis through its conversion to glutamate, as well as 174	
its participation in the biosynthetic pathways of other amino acids. Amino acids can be 175	
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grouped into families according to common starting products or use of common 176	
enzymes for synthesis. These consist of the following families: glutamate, serine, 177	
aspartate, pyruvate, and aromatic amino acid families, as well as several unique 178	
pathways for individual amino acids (Umbarger, 1978). It is important to note that an 179	
overwhelming amount of the literature on bacterial metabolism has historically been 180	
focused on a few bacterial taxa, namely Escherichia coli and Salmonella typhimurium, 181	
and to a lesser extent Bacillus subtilis and recently Corynebacterium glutamicum, thus 182	
creating a potential bias towards mechanisms found in these organisms. Although many 183	
of these pathways are conserved across bacterial lineages including those inhabiting the 184	
intestine, diversity is found among different bacterial species at both the species and 185	
strain level.  For example, whole genome analysis has revealed that the common gut 186	
bacterium Clostridium perfringens lacks numerous amino acid biosynthetic genes for 187	
glutamate, arginine, histidine, lysine, methionine, serine, threonine, aromatic and 188	
branched-chain amino acids (Shimizu, et al., 2002), while other Clostridium spp., such 189	
as Clostridium acetobutylicum, has a complete set of genes for amino acid biosynthesis 190	
(Nolling, et al., 2001).  The gut bacterium Lactobacillus johnsonii also appears 191	
incapable of carrying out de novo biosynthesis of almost all amino acids due to a lack of 192	
complete biosynthetic pathways, and exhibits an apparent dependence on exogenous 193	
host amino acids/peptides for protein synthesis (Pridmore, et al., 2004). Other animal 194	
and human intestinal bacteria, including Campylobacter jejuni, Helicobacter pylori, 195	
Enterococcus faecalis and Streptococcus agalactiae have also lost certain amino acid 196	
biosynthetic pathways (Yu, Walker, Liu, & Zhang, 2009), suggesting a dependence on 197	
availability of exogenous peptides/amino acid sources. Furthermore, the sole presence 198	
of genes within a genome does not confirm their functionality. Genes for the 199	
biosynthesis of all 20 standard amino acids have been identified in the common gut 200	
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bacterium Lactococcus lactis, although supplemented sources of certain amino acids 201	
(isoleucine, valine, leucine, histidine, methionine, and glutamic acid) are also required 202	
for growth since genes in these biosynthetic pathways have been demonstrated to be 203	
non-functional due to point mutations (Bolotin, et al., 2001; Godon, et al., 1993). This 204	
may also be the case with another gut bacterium Staphylococcus aureus, as two distinct 205	
strains exhibited auxotrophy for different amino acids, despite the presence of complete 206	
sets of genes for biosynthetic pathways of these essential amino acids in both strains 207	
(Kuroda, et al., 2001).  Given these different scenarios, it is likely that alternative 208	
intestinal bacterial co-metabolic pathways and regulation strategies remain to be 209	
discovered.  210	
 211	
Glutamate Family (glutamate, glutamine, proline, arginine) 212	
 Glutamate and glutamine are both key nitrogen/amino group donors for amino acid 213	
synthesis and provide the major entry points of ammonia into bacterial metabolism (H. 214	
Shimizu & Hirasawa, 2007). These enzyme pathways are particularly important for 215	
some gut bacteria with a reliance on ammonia as a nitrogen source, such as many 216	
Bacteroides spp., which cannot replace ammonia with other nitrogen sources such as 217	
amino acids, peptides, urea or nitrate (reviewed in Fischbach & Sonnenburg, 2011). 218	
Glutamate is one of the most important central metabolites in all bacteria providing a 219	
link between carbon and nitrogen metabolism. Most enteric bacteria have two primary 220	
pathways for the synthesis of glutamate (Fig. 1a) involving either the enzyme glutamate 221	
dehydrogenase (GDH) or glutamine oxoglutarate aminotransferase (also called GOGAT 222	
or glutamate synthase) (Reitzer & Magasanik, 1987; H. Shimizu & Hirasawa, 2007). 223	
Preferential use of either pathway depends on both the energy state and intracellular 224	
ammonium concentrations in the cells. GDH is preferentially utilized for glutamate 225	
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synthesis when both energy and carbon sources are limited for the cell but ammonium 226	
and phosphate are present in excess, while the GOGAT pathway is preferred when the 227	
cell is not under energy limitation since this pathway requires the expenditure of ATP 228	
(Helling, 1994). However, exceptions to this strategy are seen in the common gut 229	
bacterium Bacteroides fragilis which contains 2 distinct glutamate dehydrogenase 230	
enzymes: a dual cofactor NAD(P)H-dependent (gene = gdhB) enzyme whose activity 231	
depends on high ammonia concentrations, and a NADH-specific enzyme whose activity 232	
depends on high peptide concentrations in which ammonia has no effect on activity 233	
(Abrahams & Abratt, 1998; Yamamoto, Saito, & Ishimoto, 1987). In the Gram-positive 234	
bacterium Bacillus subtilis, glutamate is exclusively synthesized by reductive amination 235	
of α-ketoglutarate by the enzyme glutamate synthase encoded by the gltAB operon 236	
(Belitsky, 2002). 237	
 Glutamine is synthesized by the single reaction of glutamine synthetase (GS; EC 238	
6.3.1.2) in which ammonia is added to glutamate through ATP hydrolysis (Fig. 1a). 239	
Three distinct types of glutamine synthetases have been identified in bacteria: GSI is 240	
found in eubacteria and archaea including the ruminal R. albus, GSII is present only in 241	
eukaryotes and several soil bacteria: Rhizobium, Frankia, and Streptomyces, while 242	
GSIII has only been found in several unrelated bacteria Bacteroides fragilis, Rhizobium 243	
leguminosarum, and Butyrivibrio fibrisolvens, and R. albus (Brown, Masuchi, Robb, & 244	
Doolittle, 1994; Kim, Henriksen, Cann, & Mackie, 2014). 245	
 Several pathways exist for bacterial proline biosynthesis, however the most common 246	
pathway found in many groups involves a four-step process starting with the 247	
phosphorylation of glutamate (Fig. 1a) (reviewed in (Fichman, et al., 2014). Genomic 248	
analysis of proline biosynthesis has revealed that many eubacterial and archael species 249	
contain only one recognizable gene from this pathway (i.e. Δ1-pyrroline-5-carboxylate 250	
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reductase) while other species lack all genes from this pathway, suggesting that either 251	
these bacteria are dependent on exogenous proline sources for growth or that alternative 252	
pathways may exist that may not yet be elucidated (Fichman, et al., 2014). 253	
 Biosynthesis of arginine involves an eight-step process starting with the acetylation 254	
of the glutamate (Fig. 1a).  This step occurs through the so-called “classical” pathway 255	
initially described for E. coli via the enzyme N-acetylglutamate synthase (NAGS) and 256	
encoded by the gene argA  (reviewed in (Xu, Labedan, & Glansdorff, 2007).  In many 257	
bacterial species, this step can also be achieved by an ornithine N-acetyltransferase 258	
(OAT) with dual functional activities (E.C. 2.3.1.35 / 2.3.1.1) that can also synthesize 259	
acetylglutamate de novo from acetyl-CoA and glutamate (Marc, et al., 2000; Xu, et al., 260	
2007).  261	
 262	
Serine Family (serine, glycine, cysteine) 263	
 Serine is an important metabolite and precursor to multiple amino acids in bacteria 264	
(glycine, cysteine, tryptophan).  It is also a precursor for the metabolism of 265	
sphingolipids, folate, methane, sulfur, cyanoamino acid, and pyruvate, and also 266	
participates in the biosynthesis of purines and pyrimidines (Stolz, et al., 2007; 267	
Umbarger, 1978). Furthermore, L-serine plays a fundamental role in stabilizing blood 268	
sugar concentration in the liver (Remesy, Fafournoux, & Demigne, 1983).  Synthesis of 269	
serine is a three-step process starting with the glycolytic intermediate 3-270	
phosphoglycerate (Fig. 1b) (Peters-Wendisch, et al., 2005). Glycine is generated from 271	
serine by the single enzyme serine hydroxymethyltransferase (Fig. 1b) that catalyzes the 272	
reversible conversion of serine and tetrahydrofolate to glycine and 5,10-methylene 273	
tetrahydrofolate, which is a key intermediate in the biosynthesis of purine, thymidine, 274	
choline, glutathione and methionine (Trivedi, et al., 2002). In enterobacteria and 275	
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Bacillus subtilis, the synthesis of cysteine is a two-step reaction (Fig. 1b) that involves 276	
the substrates coenzyme A and hydrogen sulfide (H2S) (Kredich, 1996).  277	
Bifidobacterium longum lacks the genes for the final step with cysteine synthase and 278	
may use alternative pathways with several enzymes such as succinylhomoserine and the 279	
sulfur-containing compounds H2S or methanethiol produced by other colonic bacteria 280	
(Schell, et al., 2002). Several strains of Bifidobacterium bifidum have further displayed 281	
cysteine auxotrophy (Ferrario, et al., 2015), indicating a dependence of exogenous 282	
sources of this amino acid. 283	
 284	
Aspartate Family (aspartate, asparagine, lysine, threonine, methionine) 285	
 Aspartate is an important precursor for the biosynthesis of numerous amino acids. It 286	
is synthesized from the transfer of an amino group from glutamate to oxaloacetate via 287	
the enzyme aspartate transaminase (Fig. 2). Asparagine is commonly made by one of 288	
two distinct asparagine synthetases in bacteria in which one enzyme utilizes ammonia 289	
while the other synthetase carries out a transamination reaction from glutamine to 290	
aspartate (Fig. 2) (Min, Pelaschier, Graham, Tumbula-Hansen, & Soll, 2002). Alternate 291	
pathways exist in some gut bacteria, such as B. longum, which lack both types of 292	
asparagine synthetases and likely use an asparaginyl-tRNA-dependent route (Schell, et 293	
al., 2002). 294	
 Two main pathways exist for lysine biosynthesis in bacteria, the diaminopimelic acid 295	
(DAP) and aminoadipic acid (AAA) pathways.  The DAP pathway is used by most 296	
bacteria and some archaea and utilizes aspartate and pyruvate as starting material with 297	
meso-2-6-diaminopimelic acid as an intermediate (Fig. 2) (Patte, 1996).  Four variations 298	
of this pathway have been identified in bacteria: the succinylase (most common) (Fig. 299	
2), acetylase, aminotransferase, and dehydrogenase pathways (Liu, White, & Whitman, 300	
	 13
2010). No organism is known to possess both DAP and AAA pathways (Liu, et al., 301	
2010).  In E. coli, the first step in the DAP pathway employs three distinct aspartate 302	
kinase isozymes (ThrA, MetL, and LysC), each specific to one of three different 303	
biochemical pathways under regulation from lysine, methionine, and threonine 304	
(Vitreschak, Lyubetskaya, Shirshin, Gelfand, & Lyubetsky, 2004). 305	
 Synthesis of threonine shares the first two steps of the biosynthetic pathway of lysine 306	
(Fig. 2). In addition to the conversion of aspartate to 4-phospho-L-aspartate, ThrA and 307	
MetL isozymes also contain a homoserine dehydrogenase (Hom) domain that carries 308	
out the third step in the biosynthetic pathway in which aspartate 4-semialdehyde is 309	
converted to homoserine (Fig. 2) (Vitreschak, et al., 2004). Methionine shares the first 310	
three steps of the biosynthetic pathway of threonine (Fig. 2); after which several 311	
different pathways are utilized by different bacteria to attach a sulfur group to O-312	
Succinyl-L-homoserine via either L-cysteine (Fig. 2) or incorporate inorganic sulfur 313	
with O-acetylhomoserine to form homocysteine (Rodionov, Vitreschak, Mironov, & 314	
Gelfand, 2004). 315	
 316	
Pyruvate Family (isoleucine, valine, leucine, alanine) 317	
 The branched-chain amino acids (BCAA), valine, leucine and isoleucine share 318	
common biosynthetic pathways all stemming from intermediates from pyruvate 319	
metabolism. These pathways are so similar that many of the same enzymes are shared 320	
for biosynthesis of all these amino acids (Fig. 3).  In E. coli and S. enterica serovar 321	
Typhimurium, three different isoenzymes of the enzyme acetolactate synthase (AHAS; 322	
EC 2.2.1.6;) are made up of a large and small subunit encoded by the respective genes 323	
ilvIH, ilvBN, and ilvGM (Umbarger, 1996). Isoleucine biosynthesis starts with the 324	
conversion of threonine to 2-oxobutanoate via the enzyme threonine deaminase and 325	
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then uses the same enzymes as those described for valine biosynthesis (Fig. 3). Leucine 326	
biosynthesis uses the last intermediate from the valine pathway, 2-oxoisovalerate, to 327	
carry out the initial reaction (Fig. 3) (Pátek, 2007). Leucine has also been demonstrated 328	
to be biosynthesized via the precursor SCFA isovalerate via carboxylation in the gut 329	
bacteria Bacteroides fragilis and Prevotella ruminicola (previously Bacteroides 330	
ruminicola) (Allison, Baetz, & Wiegel, 1984). Both of these bacteria also preferentially 331	
utilize 2-methylbutyrate as a precursor for isoleucine biosynthesis instead of carrying 332	
out de novo synthesis starting from glucose (Allison, et al., 1984). Several pathways 333	
exist for alanine biosynthesis, with starting precursors such as pyruvate and aspartate 334	
among the most common (Fig. 3).  L-alanine is mainly synthesized from pyruvate and 335	
glutamate via an alanine transaminase (Oikawa, 2007). 336	
 337	
Aromatic Family (phenylalanine, tyrosine, tryptophan) 338	
 Biosynthesis of aromatic amino acids typically follows the shikimate pathway and 339	
starts with the condensation of the glycolytic intermediate phosphoenolpyruvate and the 340	
pentose phosphate pathway intermediate erythrose 4-phosphate, via the enzyme 3-341	
Deoxy-D-arabinoheptulosonate 7-phosphate (DAHP) synthase (Fig. 4) (Sprenger, 342	
2007).  In E. coli, three distinct isoenzymes (called AroF, AroG and AroH) are involved 343	
in this step and each is specifically feed-back inhibited by the terminal end products 344	
tyrosine, phenylalanine and tryptophan, respectively (Sprenger, 2007). A single non-345	
homologous DAHP synthase (AroA) is found in the Gram-positive B. subtilis (Panina, 346	
Vitreschak, Mironov, & Gelfand, 2003).  The pathway proceeds for 6 steps to the 347	
common intermediate chorismate, which serves as a branchpoint to the individual 348	
pathways for phenylalanine, tryptophan and tyrosine (Fig. 4). 349	
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 Alternative pathways exist for synthesis of each respective aromatic amino acid in 350	
different bacterial species, but commonalities within the pathways remain. The first 351	
reaction for both phenylalanine and tyrosine uses the enzyme chorismate mutase to 352	
convert chorismate to prephenate. In E. coli, chorismate mutases are bifunctional 353	
enzymes which can participate in the first two steps of both phenylalanine and tyrosine 354	
biosynthesis from chorismate (Fig. 4) (Sprenger, 2007). In E. coli, both pathways then 355	
use either the enzyme aromatic amino acid aminotransferase or aspartate 356	
aminotransferase (EC 2.6.1.1) to catalyze the transamination reaction into each 357	
respective α-keto acid using glutamate as the amino group donor (Pittard, 1996) (Fig. 358	
4).  Aromatic amino acid aminotransferase can also participate in an alternative pathway 359	
that catalyzes the conversion of prephenate to L-arogenate which can be further 360	
converted to either phenylalanine or tyrosine using prephenate dehydratase or 361	
cyclohexadieny/prephenate dehydrogenase, respectively. Instead of de novo synthesis of 362	
phenylalanine, several gut bacteria (B. fragilis and P. ruminicola) preferentially use 363	
phenylacetate as a precursor for this amino acid (Allison, et al., 1984). 364	
 Tryptophan biosynthesis is five-step pathway from chorismate (Fig. 4) in which 365	
glutamine or ammonia is used in the first step with anthranilate synthase (Nichols, 366	
1996; Pittard, 1996). In the final step, serine is used as the amino group donor for 367	
tryptophan synthase (Sprenger, 2007). The tryptophan biosynthesis pathway is quite 368	
conserved in different bacteria, although differences in gene order and the enzymatic 369	
reactions carried out by separate or fused enzyme units exist in different bacteria 370	
(reviewed in Xie, Keyhani, Bonner, & Jensen, 2003). For example, all of the genes in 371	
the biosynthetic pathway for tryptophan have been identified in the gut bacterium B. 372	
longum except for TrpF (phosphoribosylanthranilate isomerase), indicating a 373	
replacement of this gene with an unidentified homolog (Schell, et al., 2002). 374	
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 375	
Histidine 376	
 Histidine biosynthesis is a complex ten-step enzymatic pathway (Fig. 5) encoded by 377	
eight different genes, three of which (hisD, hisB, and hisI) encode bifunctional enzymes 378	
(reviewed in (Alifano, et al., 1996). Most of the work on the histidine biosynthetic 379	
pathway has mainly been studied in E. coli and Salmonella typhimurium and more 380	
recently in the industrially important Corynebacterium glutamicum, demonstrating large 381	
conservation along with some differences in the biochemical pathways between the 382	
different species (Kulis-Horn, Persicke, & Kalinowski, 2014). Whole genome studies in 383	
bacteria identified in the gut such as L. lactis confirm the presence of all the genes of 384	
this pathway (Bolotin, et al., 2001). 385	
 386	
 387	
3. Overview of uptake systems and catabolism of proteins/amino acids in gut 388	
bacteria 389	
 390	
3.1. Protein hydrolysis and peptide/amino acid transporters  391	
 Initial steps of bacterial protein catabolism include the extracellular hydrolysis of 392	
proteins via different bacterial proteases. According to the MEROPS peptidase database 393	
(Rawlings, Waller, Barrett, & Bateman, 2014), bacteria contain a highly diverse number 394	
of different proteases, present in many common gut microbiota species such as 395	
Clostridium spp. Bacteroides spp., Lactobacillus spp., etc. containing up to hundreds of 396	
different identified proteases. Some bacteria, such as lactic acid bacteria, have 397	
developed sophisticated proteolytic systems to compensate their reduced capabilities for 398	
amino acid biosynthesis (Pessione, 2012). Proteolytic systems in lactic acid bacteria 399	
	 17
consist of either extracellular or membrane-bound proteases (principally PrtP and CEP) 400	
that degrade proteins into oligopeptides, followed by their incorporation into the cell via 401	
peptide transporters (Opp, Dpp, Dtp, for oligopeptide, dipeptide, and di- and tripeptide, 402	
respectively) and finally numerous intracellular peptidases that degrade the peptides 403	
into short peptides and amino acids (reviewed in Liu, Bayjanov, Renckens, Nauta, & 404	
Siezen, 2010; Steiner, Naider, & Becker, 1995). 405	
 Amino acids and their derivatives are imported and exported from the bacterial cell 406	
via transmembrane proteins comprising ATP-dependent ABC transporters, several 407	
families of channel proteins, or secondary carriers relying on proton-motive force, 408	
sodium-ion motive force, solute-solute exchange, or uniport (Saier, 2000).  Efflux 409	
systems for some amino acids such as lysine, arginine, threonine, cysteine, leucine, 410	
isoleucine, and valine are well-known in the bacteria E. coli and Clostridium 411	
glutamicum (Eggeling & Sahm, 2003), whereas to date no export systems for histidine 412	
have been described in any organism (Kulis-Horn, et al., 2014).  413	
 414	
3.2. Transamination, deamination and decarboxylation 415	
 Bacteria may directly incorporate available amino acids as substrates for protein 416	
biosynthesis or may carry out catabolic reactions to use them as energy sources or to 417	
produce other metabolites. Under aerobic conditions, bacteria typically convert 418	
proteinogenic α-amino acids to α-oxo acids (aka. α-ketoacids) or saturated fatty acids 419	
via transamination or deamination, which are further oxidized as energy sources in the 420	
tricarboxylic acid (TCA) cycle.  However, in the absence of oxygen or other suitable 421	
electron acceptors, only strict or facultative anaerobic bacteria in the gut, such as 422	
Clostridia and Fusobacteria, are capable of utilizing amino acids as energy sources, thus 423	
fermenting amino acids to short-chain fatty acids (SCFAs), molecular hydrogen (H2), 424	
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carbon dioxide (CO2), and ammonia, with minor products of H2S, methylmercaptane, 425	
phenols, alcohols and organic acids (Davila, et al., 2013; J. Kim, Hetzel, Boiangiu, & 426	
Buckel, 2004). Several mechanisms for α-amino acid degradation exist for anaerobic 427	
bacteria, which includes the well-known Stickland reaction found in many proteolytic 428	
Clostridia which involves the coupled oxidation and reduction of two respective amino 429	
acids to organic acids. Other fermentation pathways found in various Clostridia as well 430	
as Fusobacterium spp. and Acidaminococcus spp. involve single amino acids that act as 431	
electron donors as well as acceptors (Fischbach & Sonnenburg, 2011; J. Kim, et al., 432	
2004). The genus Clostridium contains unique amino acid degradation pathways, such 433	
as B12-dependent aminomutases, selenium containing oxidoreductases and oxygen-434	
sensitive 2-hydroxyacyl-CoA dehydratases (Fonknechten, et al., 2010). 435	
 Amino acids can also be metabolized through decarboxylation reactions ultimately 436	
yielding amines and polyamines as products. Factors such as pH can influence the 437	
activity of deaminases and decarboxylases, ultimately affecting the accumulation of 438	
specific end products. Furthermore, many complex amino acids can undergo a series of 439	
metabolic reactions that produce a large variety of structurally-related metabolic end-440	
products (Davila, et al., 2013). 441	
 Amino acid utilization may be achieved in a preferential manner, as Fonknechten et 442	
al. (2010) demonstrated that Clostridium sticklandii preferentially used threonine, 443	
arginine and serine for carbon and energy sources, but hardly utilized glutamate, 444	
aspartate and aromatic amino acids, even though these catabolic pathways are found in 445	
this organism. Furthermore, lysine degradation, which is a process that provides a major 446	
energy source, was only observed in stationary growth phases (Fonknechten, et al., 447	
2010). 448	
  449	
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3.3. Factors influencing protein fermentation:  450	
 Many different factors may influence protein fermentation in the gut, such as 451	
substrate availability, transit time, pH and osmolarity. The ratio of available 452	
carbohydrates:protein determines substrate utilization by the gut microbiota (Smith & 453	
Macfarlane, 1996), and in humans, it has been shown that availability of complex 454	
carbohydrates lowers protein fermentation (Birkett, Muir, Phillips, Jones, & O'Dea, 455	
1996; De Preter, et al., 2008; Geboes, et al., 2006). When the main energy sources (i.e. 456	
fermentable carbohydrates) for microbiota are abundant, nitrogenous substrates can be 457	
used for biosynthetic (anabolic) process and bacterial growth. On the contrary, proteins 458	
are catabolized by bacteria when energy is scarce, leading to the production of amino 459	
acid-derived end products. Due to high carbohydrate fermentation in the proximal 460	
colon, there is a progressive decrease of carbohydrate availability in the distal colon, 461	
resulting in higher protein fermentation (Macfarlane, Gibson, & Cummings, 1992). 462	
Long transit time and elevated pH are also associated with high levels of protein 463	
fermentation (Cummings, Hill, Bone, Branch, & Jenkins, 1979; Macfarlane, Cummings, 464	
Macfarlane, & Gibson, 1989). Therefore, dietary carbohydrate and protein ratios may 465	
strongly influence the metabolic pathways activated in the large intestine and flow of 466	
metabolites generated.    467	
 468	
 469	
4. Key intermediate products from bacterial protein/amino acid catabolism and 470	
effects on host physiology/health 471	
 Fermentation of amino acids derived from endogenous luminal and dietary protein 472	
by intestinal microbiota produces numerous metabolites with suspected or established 473	
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effects on host intestinal physiology, liver and peripheral tissues. Relevant examples of 474	
such metabolites are described below. 475	
 476	
4.1. Microbially-produced compounds with neuroactive properties 477	
 Recent evidence has shown that bacteria isolated from the mammalian gut have the 478	
capacity to synthesize neuroactive compounds including neurotransmitters, many of 479	
which result from the catabolism of amino acids. These compounds include GABA 480	
(produced by Lactobacillus spp., Bifidobacterium spp., and Lactococus lactis); 481	
norepinephrine (produced by Escherichia spp. and Bacillus spp.); dopamine (produced 482	
by Bacillus spp.); histamine (produced by numerous bacterial genera); and serotonin 483	
(produced by Streptococcus spp., Escherichia spp. and Enterococcus spp.) (Sanders, et 484	
al., 1998; Wall, Ross, & Stanton, 2014). In addition, bacteria have been demonstrated to 485	
produce other neuroactive compounds from amino acid degradation such as nitric oxide 486	
and the biogenic amines tryptamine and phenethylamine. It is worth noting that for most 487	
of these bacterial metabolites, the understanding of their precise effects on the intestine 488	
and peripheral tissues remains in its infancy. 489	
 γ-aminobutyrate (GABA), known as an inhibitory neurotransmitter, is microbially-490	
produced by the decarboxylation of glutamate via the enzyme glutamate decarboxylase 491	
(Table 1). This enzyme makes up part of the glutamate decarboxylase (GAD) system 492	
found in several bacterial genera, which is implicated in acid tolerance by maintaining 493	
intracellular pH homeostasis through proton consumption (Feehily & Karatzas, 2013). 494	
Other factors in addition to acidic stress have been demonstrated to activate the GAD 495	
system, including sodium, polyamines and hypoxia (Feehily & Karatzas, 2013).  GABA 496	
is subsequently exported from the cell via antiporters that import glutamate, or it 497	
remains in the cells and is metabolized to succinate via the GABA shunt pathway 498	
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(Feehily & Karatzas, 2013; Karatzas, Brennan, Heavin, Morrissey, & O'Byrne, 2010). 499	
Glutamate/GABA antiporters are found in numerous Gram-negative (Escherichia, 500	
Shigella, Brucella) and Gram-positive genera (Listeria, Lactobacillus, Lactococcus, 501	
Clostridium, Bifidobacterium) (Feehily & Karatzas, 2013). An in vivo study in mice 502	
also revealed that chronic administration of Lactobacillus rhamnosus (JB-1) induced 503	
changes in mRNA of GABA receptors B1b and A2, as well as reduced anxiety- and 504	
depression-related behavior (Bravo, et al., 2011), although the direct production of 505	
GABA by gut bacteria was not investigated. In vivo studies are required to evaluate 506	
whether gut microbiota derived GABA is active on the host.  507	
 Serotonin, a neurotransmitter involved in numerous processes including behavior, 508	
learning, appetite and glucose homeostasis, is produced in the human brain but also 509	
notably in intestinal enteroendocrine cells (El-Merahbi, Loffler, Mayer, & Sumara, 510	
2015). The key role of serotonin in the gut-brain axis has been extensively reviewed, 511	
indicating that peripherally it is involved in modulation of the gut immune system, 512	
gastrointestinal secretions, motility and visceral sensitivity and centrally in mood and 513	
cognition (O'Mahony, Clarke, Borre, Dinan, & Cryan, 2015). In humans, serotonin is 514	
produced from tryptophan degradation in a two-step process via the enzymes tryptophan 515	
5-monooxygenase (tryptophan hyroxylase 1) and aromatic-L-amino-acid decarboxylase 516	
(Table 1). It has been experimentally demonstrated in vitro that serotonin can also be 517	
produced by several bacterial genera isolated from the human gut, including 518	
Streptococcus, Escherichia, Enterococcus, Lactococcus and Lactobacillus (Wall, et al., 519	
2014). However, the full mechanism of direct serotonin production by bacteria has not 520	
been clearly established. Analysis of the serotonin biosynthetic pathway in bacteria via 521	
the KEGG database reveals that several bacterial genera contain homologous genes for 522	
encoding aromatic-L-amino-acid decarboxylase used in the second step of this pathway 523	
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(Kanehisa, et al., 2014), but no homologous genes have presently been found for 524	
tryptophan 5-monooxygenase. Bacteria can also directly interact with the host to induce 525	
the production of serotonin by the host, with experimentally demonstrated effects on 526	
host physiology (Yano, et al., 2015). A comparison between germ-free mice and 527	
colonized mice (with either mouse or human gut microbiota) has shown that microbiota 528	
increased colonic expression of tryptophan hydroxylase 1, the rate limiting enzyme for 529	
mucosal serotonin synthesis, and thereby serotonin production, likely acting through 530	
SCFAs (Reigstad, et al., 2015). 531	
 Histamine and its receptors were first described as part of the immune and 532	
gastrointestinal systems, but their presence in the central nervous system and 533	
implication in behavior and energy homeostasis is gaining increasing attention 534	
(Baronio, et al., 2014). Production of histamine from the decarboxylation of the amino 535	
acid histidine has been well demonstrated in numerous Gram-positive and Gram-536	
negative bacterial strains (Landete, De las Rivas, Marcobal, & Munoz, 2008).  Gram-537	
positive bacteria, such as lactic acid bacteria, use a pyruvoyl-dependent histidine 538	
decarboxylase (EC 4.1.1.22) (Table 1), whereas Gram-negative bacteria use a pyridoxal 539	
phosphate-dependent histidine decarboxylase (Landete, De las Rivas, et al., 2008).  In 540	
Lactobacillus spp. histamine is readily exported from the cell using electrogenic 541	
histidine/histamine antiporters (Molenaar, Bosscher, ten Brink, Driessen, & Konings, 542	
1993).  Bacterial histamine production can exert both positive and negative effects on 543	
human health. Recently, Thomas et al. (2012) demonstrated that histamine derived from 544	
a human gut isolate of the species Lactobacillus reuteri suppresses pro-inflammatory 545	
TNF-α production in isolated Toll-like receptor 2-activated human monocytoid cells, 546	
indicating a potential beneficial effect of microbially-derived compounds for 547	
inflammatory conditions. However, histamine production by bacteria has also been 548	
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implicated in food poisoning related to the ingestion of fish fermented by histamine-549	
producing bacteria (scombrotoxin) (Bjornsdottir-Butler, Green, Bolton, & McClellan-550	
Green, 2015). 551	
 Tyrosine is a precursor for several hormones including the thyroid hormones 552	
thyroxine (3,5,3',5'-tetraiodothyronine) and triiodothyronine, as well as a precursor to L-553	
dihydroxyphenylalanine (L-DOPA) which is in itself a precursor to the catecholamine 554	
neurotransmitters dopamine, norepinephrine and epinephrine. Bacterial tyrosinases (EC 555	
1.14.18.1) (Table 1), which catalyze the conversion of tyrosine to L-DOPA, are widely 556	
found in many bacterial genera (Claus & Decker, 2006). Although Escherichia spp. and 557	
Bacillus spp. have been reported to produce norepinephrine (Wall, et al., 2014), 558	
enzymes necessary for production of the catecholamines norepinephrine and 559	
epinephrine have only been identified to date in animals, suggesting some mode  of 560	
cooperation between host and gut microbes in the catecholamine biosynthetic process. 561	
However, catecholamine stress hormones have been demonstrated to promote both 562	
bacterial growth and virulence (Freestone, 2013). Some opportunistic pathogens 563	
inhabiting the intestinal tract (Escherichia coli, Staphylococcus aureus, etc.) are 564	
equipped with catechol siderophore uptake systems that facilitate the import Fe(III)-565	
catecholamine complexes and, thereby, their growth under iron-restricted conditions 566	
(Beasley, Marolda, Cheung, Buac, & Heinrichs, 2011). 567	
 Tyramine is a biogenic amine capable of causing food poisoning if consumed at high 568	
levels and is involved in hypertension and migraine syndromes (Marcobal, De las 569	
Rivas, Landete, Tabera, & Munoz, 2012; Millichap & Yee, 2003). Tyramine is 570	
produced by the decarboxylation of tyrosine by the bacterial enzyme tyrosine 571	
decarboxylase (Table 1), which has been identified in Gram-positive bacteria such as 572	
lactic acid bacteria, but putative tyrosine decarboxylases in Gram-negative bacteria 573	
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remain to be characterized (Marcobal, et al., 2012). Tyramine is exported from bacterial 574	
cells via a tyrosine-tyramine antiporter (Linares, Fernandez, Martin, & Alvarez, 2009). 575	
In Gram-positive bacteria, high concentrations of tyrosine and acidic pH conditions 576	
have been demonstrated to increase the transcription of tyrosine decarboxylase and the 577	
tyrosine-tyramine antiporter (Linares, et al., 2009; Marcobal, et al., 2012). Gut 578	
microbiota derived tyramine has been shown to increase circulating serotonin levels by 579	
elevating its synthesis by enteroendocrine cells (Yano, et al., 2015) although this 580	
mechanism has not been defined. 581	
    Nitric oxide (NO) is produced from the amino acid arginine by many bacterial 582	
species via the enzyme nitric oxide synthase (NOS) (Table 1), although only several 583	
bacterial homologs of mammalian NOSs have been identified to date (Sudhamsu & 584	
Crane, 2009). Little is known about the extent that microbially-produced NO impacts 585	
the human host, notably at the intestinal mucosa level, although it is known that NO is 586	
involved in immune defense mechanisms and exerts cytotoxic effects at high 587	
concentrations. 588	
 Tryptamine is a β-arylamine neurotransmitter that has numerous biological roles 589	
including a ligand for the sigma-2 receptor, a trace amine-associated receptor that 590	
increases the inhibitory responses of cells to serotonin, and an inducer of serotonin 591	
release from enteroendocrine cells which can modulate gastrointestinal motility and 592	
may play a role in the pathology of inflammatory bowel diseases (Williams, et al., 2014 593	
and references therein). Recently it was demonstrated that tryptamine is produced by 594	
Clostridium sporogenes by the decarboxylation of tryptophan via a Trp decarboxylase 595	
(Table 1) (Williams, et al., 2014).  Williams et al. (2014) also used a phylogenic-596	
informed screening of other decarboxylases from the gut microbiota to show that a 597	
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second Trp decarboxylase appears in the Firmicute Ruminococcus gnavus, and similar 598	
enzymes were found in at least 10% of the human population.  599	
 Phenethylamine is a trace amine that acts as a neurotransmitter and, depending on the 600	
concentrations, is associated with specific psychological disorders (Irsfeld, Spadafore, 601	
& Pruss, 2013) and can affect satiety and mood (Pessione, 2012). Phenethylamine is 602	
produced in bacteria by the decarboxylation of phenylalanine (Diaz, Ferrandez, Prieto, 603	
& Garcia, 2001) via the enzyme aromatic-L-amino-acid decarboxylase (Table 1). 604	
Potential physiological effects of microbially-derived phenethylamine on host health 605	
have yet to be elucidated.  606	
 607	
4.2. Short- and branched-chain fatty acids 608	
 The main short-chain fatty acids (SCFAs) produced in the large intestine by the 609	
mammalian gut microbiota are acetate, butyrate and propionate (Rechkemmer, Ronnau, 610	
& von Engelhardt, 1988). Although it is well known that dietary substrates for SCFA 611	
production are mainly fibers and resistant starches (Laparra & Sanz, 2010), isolated 612	
colonic bacteria growing in vitro on proteins as the only available carbon source have 613	
been demonstrated to produce SCFAs as well as branched-chain fatty acids (BCFAs) 614	
(Neis, et al., 2015). Bacterial fermentation of glycine, alanine, threonine, glutamate, 615	
lysine and aspartate can produce acetate; threonine, glutamate and lysine can produce 616	
butyrate, and alanine and threonine can produce propionate (Davila, et al., 2013). 617	
Nonetheless, the molecular pathways involved in production of these SCFAs are not 618	
well-defined.  619	
 Branched-chain fatty acids (BCFAs), namely isobutyrate, 2-methylbutyrate and 620	
isovalerate, are derived from branched-chain amino acids and are present at much lower 621	
concentrations in the large intestine luminal content (Liu, et al., 2014). Although a full 622	
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description of bacterial synthesis of BCFA from amino acids is beyond the scope of this 623	
article, many Gram-positive bacteria use the primers isovaleryl-CoA, isobutyryl-CoA, 624	
and 2-methylbutyryl-CoA derived from valine, isoleucine, and leucine to produce 625	
BCFA using a specialized branched-chain-keto acid dehydrogenase complex (Cronan & 626	
Thomas, 2009). The relative proportions of SCFAs and BCFAs depend on numerous 627	
factors including the type of protein degraded as well as the available concentrations of 628	
carbohydrates (Macfarlane & Macfarlane, 2012). 629	
 The SCFAs acetate, propionate and butyrate produced via bacterial fermentation of 630	
carbohydrates and/or amino acids have been proposed to exert various physiological 631	
effects, which have been recently reviewed (Hamer, et al., 2008). Briefly, for instance, 632	
butyrate provides energy to colonocytes and regulates cell proliferation and 633	
differentiation as well as the transcription of numerous genes involved in mucin 634	
production and hormone secretion (i.e. PYY, GLP-1, GLP-2) that influence gut 635	
integrity and transit, appetite and glucose metabolism (Daly, Cuff, Fung, & Shirazi-636	
Beechey, 2005). Butyrate also plays an anti-inflammatory role via different 637	
mechanisms, including inhibition of LPS-mediated inflammatory cytokine secretion by 638	
intestinal epithelial cells and other immune cells and via induction of colonic regulatory 639	
T cells partly by an epigenetic modification of the forkhead box-P3 promoter 640	
(Furusawa, et al., 2013). Propionate and acetate undergo partial oxidation in 641	
colonocytes or can travel to the liver via the portal vein where they serve as substrates 642	
for gluconeogenesis and lipogenesis (Tremaroli & Backhed, 2012). Acetate is also a 643	
substrate for cholesterol synthesis, whereas propionate can decrease cholesterol 644	
synthesis (Demigne, et al., 1995). In addition, SCFAs are ligands for G protein-coupled 645	
receptors, namely Gpr41 and Gpr43, which are expressed in enteroendocrine L-cells of 646	
the distal small intestine and colon (Reigstad, et al., 2015). Gpr41 deficiency has been 647	
	 27
shown to be associated with reduced expression of peptide YY (PYY), a gut hormone 648	
involved in satiety and gut motility (Samuel, et al., 2008). Direct administration of 649	
SCFAs in the colon increase PYY plasma level, and in vitro administration on primary 650	
colonic crypts also increase the release of PYY, suggesting a direct effect of SCFA on 651	
secretion (Chambers, et al., 2014; Cherbut, et al., 1998). Butyrate can also bind the 652	
GPR109a receptor expressed by intestinal macrophages and dendritic cells, thus 653	
activating production of the anti-inflammatory cytokine Il-10 (Pabst & Bernhardt, 654	
2010). BCFAs have also been shown to regulate electrolyte absorption and secretion 655	
(Musch, Bookstein, Xie, Sellin, & Chang, 2001). It has been proposed that SCFAs 656	
could exert effects beyond the gut via their interactions with Gpr expressed in different 657	
tissues and cellular types (e.g. adipocytes, pancreatic cells, neuronal cells) and thereby 658	
regulate metabolism by inducing energy expenditure and mitochondrial function (Gao, 659	
et al., 2009). Whether these effects could be mediated by the SCFAs generated by the 660	
gut microbiota requires further investigation.  661	
 662	
4.3. Sulfur-containing bacterial metabolites 663	
 Fecal S-containing substances are a complex mixture of bacterial metabolites 664	
including methanethiol and the well-studied H2S, which is found at millimolar 665	
concentrations in the human colonic luminal contents and in feces (Macfarlane, et al., 666	
1992).  In addition to production of H2S via reduction of inorganic sulfate by intestinal 667	
sulfate reducing bacteria or microbial catabolism of intestinal sulfomucins, sulfide is 668	
produced by intestinal microbiota activity through fermentation of several S-containing 669	
amino acids of both dietary and endogenous origins (Blachier, et al., 2010). H2S is 670	
notably produced as a byproduct by the bacterial fermentation of cysteine via cysteine 671	
desulfhydrases, cystathione-B-lyase and tryptophanase (Table 1) (Awano, Wada, Mori, 672	
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Nakamori, & Takagi, 2005). Fermentation of methionine yields the sulfur-containing 673	
compound methanethiol (Davila, et al., 2013). Due to its lipophilic activity, H2S 674	
penetrates biological membranes (Reiffenstein, Hulbert, & Roth, 1992) and, when 675	
present in excess, inhibits mitochondrial cytochrome c oxidase activity reversibly with a 676	
binding constant similar to cyanide (Leschelle, et al., 2005). At lower concentrations, 677	
H2S is able to increase cellular respiration and ATP production by means of the 678	
mitochondrial sulfide-oxidizing unit (Bouillaud & Blachier, 2011). Although several 679	
lines of evidence suggest that excessive concentrations of sulfide in the intestinal 680	
luminal content may be implicated in the etiology of ulcerative colitis (Pitcher & 681	
Cummings, 1996) and in the risk of relapse after an inflammatory episode (Jowett, et 682	
al., 2004), there is also evidence that endogenously-formed low levels of H2S in 683	
intestinal mucosa may participate in the resolution of mucosal inflammation (Flannigan, 684	
et al., 2015).  Experiments from colonocyte incubation and intra-colonic instillation 685	
with millimolar concentrations of NaHS, used as a H2S donor, indicate that hydrogen 686	
sulfide reversibly inhibits colonocyte oxygen consumption and increases the expression 687	
of hypoxia-inducible factor 1 alpha (HIF-1alpha) together with several inflammation-688	
related genes, namely inducible nitric oxide synthase (iNOS) and interleukin 6 (Il-6) 689	
(Beaumont, et al., 2016). Importantly, it has been demonstrated that endogenously 690	
produced H2S maintains colon cancer cellular bioenergetics supporting colonic tumor 691	
growth (Szabo, et al., 2013).  692	
 693	
4.4. Aromatic compounds 694	
 In addition to neuroactive compounds, the catabolism of aromatic amino acids 695	
(phenylalanine, tyrosine and tryptophan) by the microbiota also produces phenolic and 696	
indolic compounds (Nyangale, Mottram, & Gibson, 2012). Recent support for a role of 697	
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gut microbiota in the production of various aromatic amino acid metabolites has 698	
recently been demonstrated by comparing metabolites between specific pathogen-free 699	
(SPF) mice and germ-free (GF) mice (Sridharan, et al., 2014). However, bacterial 700	
metabolism of aromatic compounds largely depends on the type of carbon availability, 701	
as fermentable carbohydrates largely inhibit aromatic amino acid fermentation (Smith & 702	
Macfarlane, 1996). 703	
 Phenol is produced from the conversion of tyrosine via the enzyme tyrosine phenol-704	
lyase (Table 1). Optimal conditions for production of phenol by anaerobic bacteria in 705	
the human large intestine include a near-neutral pH of 6.8 and availability of free amino 706	
acids as opposed to peptides (Smith & Macfarlane, 1997). The types of intestinal 707	
bacteria may also play a significant role in production of phenol as aerobic bacteria 708	
tended to produce phenol from tyrosine degradation in vitro while anaerobic bacteria 709	
produced p-cresol (Bone, Tamm, & Hill, 1976). Phenol has been shown to decrease the 710	
integrity of the barrier function of colonocytes in vitro (Hughes, Kurth, McGilligan, 711	
McGlynn, & Rowland, 2008) and impaired the viability of human colonic epithelial 712	
cells at concentrations higher than 1.25 mM (Pedersen, Brynskov, & Saermark, 2002).  713	
 Formation of p-cresol (or 4 methylphenol) by microbes begins with the two-step 714	
conversion of tyrosine to 4-hydroxyphenylacetate (Meyer & Hostetter, 2012), although 715	
the genes involved in this conversion are unknown (Table 1) (Dawson, et al., 2011). In 716	
the final step, the bacterium Clostridium difficile uses the enzyme p-717	
hydroxyphenylacetate decarboxylase (genes hpdB, hpaC, hpdA) to convert 4-718	
hydroxyphenylacetate to p-cresol (Selmer & Andrei, 2001; Yu, Blaser, Andrei, Pierik, 719	
& Selmer, 2006).  The hpdBCA operon is rarely found in gut microflora other than 720	
Clostridium spp. (Dawson, et al., 2011), and therefore it is unknown to what extent, if 721	
any, other gut genera play a role in p-cresol formation. Production of p-cresol is 722	
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stimulated by Fe(III) and competitive growth conditions in Clostridium spp. (Doerner, 723	
Mason, Kridelbaugh, & Loughrin, 2009; Selmer & Andrei, 2001). The p-cresol 724	
concentration in human feces averages approximately 0.4 mM (Gostner, et al., 2006; 725	
Lecerf, et al., 2012). These compounds are absorbed from the intestinal lumen to the 726	
portal bloodstream through colonocytes, metabolized in the liver and finally excreted by 727	
the kidneys with more than 90% of urinary phenolic compounds being recovered as p-728	
cresol (Hughes, Magee, & Bingham, 2000). At millimolar concentrations, p-cresol 729	
inhibits human colonocyte proliferation and cell respiration and increases superoxide 730	
production (Andriamihaja, et al., 2015). Most importantly, in this latter study, p-cresol 731	
was found to be genotoxic towards human colonocytes. p-cresol can be conjugated in 732	
the colonic epithelium and in the liver, generating p-glucuronide and cresyl sufate, 733	
(Evenepoel, Meijers, Bammens, & Verbeke, 2009). Phenolic compound sulphation has 734	
been shown to be impaired in the mucosa of ulcerative colitis patients (Ramakrishna, 735	
Roberts-Thomson, Pannall, & Roediger, 1991). Interestingly, p-cresyl sulfate promotes 736	
insulin resistance in chronic kidney disease (CKD) patients (Koppe, et al., 2013) and is 737	
found at elevated concentrations in the urine of autism patients (Heinken & Thiele, 738	
2015).  It can also cause damage in renal tubular cells by induction of oxidative stress 739	
through activation of NADPH oxidase (Watanabe, et al., 2013). 740	
 Indole is produced from tryptophan via the enzyme tryptophanase (Table 1), which is 741	
found only in microbes (Meyer & Hostetter, 2012). After absorption through the 742	
intestinal epithelium, indole is transported to the liver where it undergoes hydroxylation 743	
by the host to 3-hydroxy-indole and finally sulfonated to indoxyl sulfate, a uremic 744	
toxin, via a sulfotransferase (Meijers & Evenepoel, 2011; Wikoff, et al., 2009). In 745	
contrast, indole also has a potential beneficial effect on host intestinal epithelial cells, as 746	
treatment of human enterocytes with indole was found to result in increased expression 747	
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of genes involved in the mucosal barrier functions and was associated with a reduction 748	
of inflammatory parameters (Bansal, Alaniz, Wood, & Jayaraman, 2010). Secretion of 749	
the incretin GLP-1 from enteroendocrine cells is increased during short exposures to 750	
indole via interference of voltage-gated K+ channels, but reduced over long periods of 751	
exposure to indole via slowing ATP production by blocking NADH dehydrogenase 752	
(Chimerel, et al., 2014). Besides its role in glucose metabolism through increasing 753	
insulin secretion, GLP-1 is involved in inhibiting gastric secretion and motility; these 754	
phenomenons being associated with increased satiety (Steinert, Beglinger, & Langhans, 755	
2015). The indole derivative indole-3-aldehyde was also shown to regulate gut mucosal 756	
immune response through aryl hydrocarbon receptor as well as intestinal barrier 757	
function and inflammation through its sensing by pregnane X receptor (Venkatesh, et 758	
al., 2014; Zelante, et al., 2013).  759	
 Serum levels of the amino acid tryptophan itself also have a demonstrated role in 760	
host health, as decreases in this amino acid have been associated with increased immune 761	
activation, inflammatory diseases such as Crohn’s disease, as well as cognitive deficit 762	
(Gupta, et al., 2012; Widner, et al., 1999). This may be particularly detrimental in 763	
elderly populations, as increased proportions of genes from gut microbiota involved in 764	
aromatic amino acid metabolism (including tryptophan), as well as decreased levels of 765	
tryptophan have been reported in elderly patients (Collino, et al., 2013; Rampelli, et al., 766	
2013). 767	
 768	
4.5. Polyamines 769	
 Intestinal luminal polyamines (i.e. agmatine, putrescine, spermidine, cadaverine, 770	
etc.) can originate from dietary components, microbiota metabolism (Davila, et al., 771	
2013), and endogenous origin, notably released from desquamated intestinal epithelial 772	
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cells. Gram-negative bacteria such as E. coli produce high concentrations of putrescine 773	
and spermidine in minimal media (Tabor & Tabor, 1985). Numerous amines (including 774	
polyamines) have been measured in the intestinal luminal contents at concentrations 775	
ranging from micro- to millimolar (Osborne & Seidel, 1990). Intestinal epithelial cells 776	
have the capacity to take up polyamines from the intestinal luminal contents (Blachier, 777	
et al., 1992). 778	
 Agmatine is formed by the decarboxylation of the amino acid arginine via the 779	
enzyme arginine decarboxylase (Table 1).  Agmatine, which is produced and released 780	
by colonic bacteria as well as by desquamated intestinal epithelial cells and ingested in 781	
food, exerts inhibitory effects on colonocyte proliferation (Mayeur, et al., 2005). 782	
Putrescine can be synthesized by bacteria from the amino acid arginine either through 783	
the intermediate ornithine or through agmatine (Nakada & Itoh, 2003). Agmatine is 784	
either directly converted to putrescine via the enzyme arginine decarboxylase, or goes 785	
through a two-step process which uses the enzymes agmatine deiminase and N-786	
carbamoylputrescine amidase (Table 1). The agmatine deiminase pathway has been 787	
found in several bacterial genera such as Pseudomonas, Enterococcus, Bacillus and 788	
Lactobacillus (Landete, Arena, Pardo, Manca de Nadra, & Ferrer, 2008). Agmatine-789	
putrescine antiporters have been identified in bacterial genera and function by importing 790	
agmatine and exporting putrescine (Polo, Gil-Ortiz, Cantin, & Rubio, 2012). Putrescine 791	
synthesis has been shown to be strictly necessary for colonic epithelial cell proliferation 792	
(Gamet, Cazenave, Trocheris, Denis-Pouxviel, & Murat, 1991; Mouille, Delpal, 793	
Mayeur, & Blachier, 2003). 794	
 In many bacteria including E. coli, spermidine is synthesized from putrescine and 795	
decarboxylated S-adenosylmethionine (SAM) via spermidine synthase (Tabor & Tabor, 796	
1985).  Recently, bacteria lacking spermidine synthase orthologues were discovered to 797	
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have an alternate pathway in which spermidine is formed by the enzymes 798	
carboxynorspermidine dehydrogenase (aka carboxynorspermidine synthase) and 799	
carboxynorspermidine decarboxylase via the intermediate carboxyspermidine (Lee, et 800	
al., 2009).  This alternative pathway of spermidine synthesis has been identified as the 801	
dominant pathway in the human gut microbiota as well as diverse human pathogens and 802	
is critical for growth in selected species (Hanfrey, et al., 2011). In host cells, SAM can 803	
react with spermidine via another enzyme, spermine synthase, to produce spermine. 804	
Prokaryotic cells do not appear to contain spermine synthase, but they can produce a 805	
different tetra-amine compound, thermospermine, that has been detected in lower 806	
eukaryotes and plants (Minguet, Vera-Sirera, Marina, Carbonell, & Blazquez, 2008). 807	
Spermidine and spermine are polycationic amines that are involved in numerous 808	
processes such as mitigating oxidative stress, and induction of autophagy to stimulate 809	
cellular longevity (Eisenberg, et al., 2009; Yamamoto, et al., 2012). 810	
 The polyamine cadaverine is synthesized from lysine in a one-step reaction with 811	
lysine decarboxylase (Table 1) and has been shown to provide an acid resistance 812	
mechanism in E. coli (Le Gall, et al., 2011). However, the effects of cadaverine on the 813	
colonic epithelial cells remain unknown.  814	
 815	
4.6. Ammonia 816	
 Ammonia provides the source of nitrogen for all amino acids and is primarily 817	
assimilated through either glutamate dehydrogenase or the glutamine 818	
synthetase/GOGAT cycle.  It is also used directly in the biosynthesis of various amino 819	
acids including glutamate, glutamine, asparagine, valine, isoleucine, leucine, 820	
phenylalanine, tyrosine and tryptophan (Figs. 1-4). Ammonia can be produced by the 821	
microbial degradation of numerous amino acids to specific metabolites (i.e. arginine to 822	
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putrescine, tyrosine to phenol, tryptophan to indole, Table 1). Ammonia (taken as the 823	
sum of NH3 and NH4+) is found at millimolar concentrations in the large intestine 824	
luminal content of mammals including humans (Mouille, Robert, & Blachier, 2004). In 825	
humans, the luminal ammonia concentration progressively increases from the ascending 826	
to the descending colon (Macfarlane, et al., 1992), in accordance with a higher rate of 827	
protein fermentation in the distal colon. The luminal ammonia concentration in the large 828	
intestine is primarily the net result of microbiota utilization and production through 829	
amino acid deamination, urea hydrolysis, and absorption from the luminal content to the 830	
portal blood, with the unabsorbed/unmetabolized ammonia being excreted in feces 831	
(Eklou-Lawson, et al., 2009). Although relatively large amounts of ammonia can be 832	
transferred from the intestinal lumen to the bloodstream, a part of this ammonia can be 833	
metabolized by colonocytes into citrulline and glutamine (Eklou-Lawson, et al., 2009; 834	
Mouille, et al., 2004), allowing control of the intracellular ammonia concentration in 835	
colonocytes during its transfer from the luminal content to the portal bloodstream. 836	
Ammonia inhibits mitochondrial oxygen consumption in a dose-dependent manner, 837	
leading to the concept that excessive luminal ammonia concentration behaves as a 838	
metabolic troublemaker towards colonocyte energy metabolism (Andriamihaja, et al., 839	
2010). Accordingly, high millimolar concentrations of ammonia have been shown to 840	
markedly inhibit short-chain fatty acid oxidation in isolated colonocytes (Cremin, Fitch, 841	
& Fleming, 2003). 842	
 843	
 844	
5.  Gut microbiome features related to amino acid metabolism as a function of the 845	
subject’s metabolic phenotype and the diet 846	
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 Recent metagenomic studies have allowed a detailed examination of the metabolic 847	
capacity of the mammalian gut microbiome in metabolizing nitrogenous components, 848	
particularly amino acid-related compounds. An important insight from these studies 849	
revealed that the gut microbiome contains a large enrichment of genes involved in 850	
amino acid metabolism compared to the human genome (Gill, et al., 2006), thus 851	
expanding the human metabolic capacity to form a more diverse number of metabolites. 852	
In particular, the human microbiome had large enrichments of genes involved in the 853	
biosynthesis of lysine, phenylalanine, tyrosine, tryptophan, valine, leucine and 854	
isoleucine as well as enrichment in genes associated with the metabolism of alanine, 855	
aspartate, glutamate, histidine, methionine, glycine, serine, threonine and the urea cycle, 856	
with only slight to moderate enrichments of genes for the metabolism of other amino 857	
acids and non-protein amino acids (Gill, et al., 2006).  Qin et al. (2010) also found an 858	
enrichment of genes involved in pathways such as the biosynthesis of lysine, 859	
phenylalanine, tyrosine, tryptophan, valine, leucine and isoleucine in the human gut 860	
microbiome compared to the host genome. Since biosynthetic pathways for essential 861	
amino acids do not exist in humans, it is not surprising that gut microbiota has 862	
developed a specialized set of genes and metabolic pathways for synthesizing these 863	
essential nutrients to ensure its survival. 864	
 Metagenomic sequencing analysis has shown that the metabolic phenotype (obese 865	
versus lean subjects) and the diet (e.g. high-fat diets, prebiotic intake, etc.) are 866	
associated with shifts in both specific microbiota taxonomic groups and functions of the 867	
mammalian gut microbiome, such as those involved in the metabolism of amino acids. 868	
Recent studies comparing the short-term effects of animal- and plant-based diets on the 869	
human gut microbiota and expression of metabolic-related genes using RNA-Seq 870	
revealed an increased expression of several catabolic amino acid genes for glutamine 871	
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and glutamate in animal-based diets, while increased expression of biosynthetic 872	
pathways for these amino acids was observed for plant diets (David, et al., 2014). David 873	
et al. (2014) also found that KEGG modules and pathways involved in methionine and 874	
leucine biosynthesis and cysteine metabolism were significantly associated with animal 875	
diets, while histidine biosynthesis and lysine and branched-chain amino acid 876	
degradation were significantly associated with plant diets.  877	
 In studies in rodents, Turnbaugh et al. (2006) found that KEGG pathways related to 878	
lysine biosynthesis and D-alanine metabolism were significantly enriched in the pooled 879	
cecal microbiome of ob/ob obese mice relative to the pooled lean cecal microbiome, 880	
while the KEGG pathways involved in the metabolism of glutamate, glycine, serine, 881	
threonine, cysteine, arginine and proline and the biosynthesis of phenylalanine, tyrosine 882	
and tryptophan were depleted in the ob/ob mouse microbiome relative to the lean one. 883	
Comparison of obese/lean sibling pairs of mice revealed that KEGG pathways involved 884	
in phenylalanine, tyrosine and tryptophan biosynthesis were also depleted in the cecal 885	
microbiomes of the obese mice (Turnbaugh, et al., 2006). Furthermore, using fecal 886	
samples from obese and lean human twin pairs, Turnbaugh et al. (2009) revealed a 887	
depletion of the KEGG pathway involved in tryptophan metabolism in obese twins 888	
compared to their lean counterparts. Recent studies by Everard et al. (2014) revealed 889	
that the clusters of orthologous group (COG) for amino acid transport and metabolism 890	
was enriched in both high-fat diet-fed (HFD) mice and high-fat diet-fed mice treated 891	
with the prebiotic oligofructose (HFD-Pre) compared to controls with and without 892	
prebiotic treatment, with the HFD-Pre mice yielding the highest enrichment of all 893	
groups. Nevertheless, the physiological meaning of those changes in gut microbiome 894	
amino acid metabolic pathways associated with genetically (ob/ob) or diet-induced 895	
(HFD) obesity remains unknown. Furthermore, to our knowledge there have not been 896	
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detailed metagenomic studies examining the effect of a high-protein (HP) diet in either 897	
murine models or humans. 898	
 Recent metabolomic studies have provided further evidence of the role of gut 899	
microbiota in amino acid metabolism. Zheng et al. (2011) compared metabolites 900	
produced by the host (rat) and microbiota during antibiotic administration and also after 901	
a 14-day recovery period and showed that the recovered mammalian gut microbiota 902	
alters the host’s systemic metabolism in terms of production of short chain fatty acids, 903	
tryptophan and tyrosine and possibly indole-melatonin.  Metabolomic analyses have 904	
also recently suggested that individual amino acids may play key roles in diet-related 905	
diseases. For example, high concentrations of branched-chain amino acids (BCAA) and 906	
their respective metabolites have been linked with obesity and type 2 diabetes, while 907	
aromatic amino acids and high ratios of glutamate/glutamine have also been associated 908	
with type 2 diabetes (reviewed in Heinken & Thiele, 2015).  Although the association of 909	
BCAA and other amino acids with insulin resistance and type 2 diabetes has been well-910	
known for decades, Newgard et al. (2009) recently performed metabolomic profiling of 911	
obese and lean humans to show that the addition of branched-chain amino acids (valine, 912	
leucine, isoleucine) and two aromatic acids (phenylalanine and tyrosine) to a high-fat 913	
diet contributes to the development of obesity-associated insulin resistance. Wang et al. 914	
(2011) also carried out metabolic profiling to investigate whether specific metabolites 915	
could predict diabetes development and discovered that the same five branched-chain 916	
and aromatic acids were strongly associated with the onset of diabetes, thus suggesting 917	
a potential role of amino acid metabolism in the pathogenesis of diet-related diabetes.  918	
Although the direct role of the gut microbiota in production of these amino acids has not 919	
yet been clearly defined in vivo, theoretically the gut bacteria have the capacity to 920	
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synthesize all of these essential amino acids and, thereby, play a role in those 921	
conditions. However, more work is needed to elucidate this connection. 922	
 In the case of increased dietary protein intake, the amount of undigested protein that 923	
is transferred to the large intestine markedly increases (Chacko & Cummings, 1988). 924	
Consequently, more substrate is available for bacterial amino acid catabolism. However, 925	
the consequences of this increased availability is not well described at a metabolic level 926	
as only a few studies have only partially examined microbial-derived metabolite profiles 927	
in HP diets by a non-targeted analytical approach in which all potential metabolites are 928	
analyzed.  Russell et al. (2011) demonstrated that HP diets with low and moderate 929	
carbohydrate intake in humans displayed increased branched-chain fatty acids, 930	
phenylacetic acid and N-nitroso compounds compared to a weight-maintenance diet 931	
with moderate protein levels at the beginning of the intervention study. Reduced 932	
proportions of butyrate and antioxidant phenolic acids were also detected in the HP low-933	
carbohydrate diets (Russell, et al., 2011) likely as a result of the low carbohydrate 934	
intake. Those changes in fecal metabolic profiles were associated with a decrease in 935	
proportions of the known butyrate-producing bacteria Roseburia/Eubacterium rectale 936	
(Russell, et al., 2011). Other studies in humans found that H2S fecal concentration was 937	
increased in humans fed a meat-rich diet (Magee, Richardson, Hughes, & Cummings, 938	
2000), and increased levels of phenol, p-cresol and phenylacetate have been detected in 939	
urine and feces of individuals receiving HP diets (Cummings, et al., 1979; Geypens, et 940	
al., 1997; Russell, et al., 2011). Increasing the amount of alimentary protein also results 941	
in an increase of the luminal and fecal ammonia concentration in humans (Geypens, et 942	
al., 1997).   HP diets in humans also caused elevations in plasma levels and urinary 943	
excretion of indoxyl sulfate and urinary excretion of indoxyl glucuronide, kynurenic 944	
acid and quinolinic acid (Poesen, et al., 2015). Although several of these compounds are 945	
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strictly produced only by gut microbiota, no study has effectively examined the direct 946	
role of the gut microbiota in the production of these metabolites. 947	
 In murine models, HP diets have been shown to modify the composition and the 948	
diversity of the colonic microbiota in rats, with associated changes in the total amount 949	
of ammonia, SCFAs, H2S, branched-chain fatty acids, ethanol and several organic acids 950	
(L- and D-lactate, succinate) in the colonic luminal content (Liu, et al., 2014). Although 951	
this experiment did not determine the direct role of microbiota composition and 952	
increased substrate availability in the changes observed after HP diet ingestion, it 953	
appears that both parameters are likely to be involved in such changes. A metabolomic 954	
analysis comparing a HP, low-carbohydrate (HPLC) diet to a moderate 955	
protein/carbohydrate (MPMC) diet in a rat model revealed that the HPLC diet induced 956	
weight loss and reduced adipose weight, and the plasma metabolites glucose, insulin, 957	
triglyceride, linoleate, palmitate, α-glycerophosphate and pyroglutamic acid and caused 958	
a significant increase in several plasma metabolites (i.e. urea, pyruvate, α-tocopherol, 2-959	
oxoisocaproate, and β-hydroxybutyrate) (Mu, Yang, Luo, & Zhu, 2015). In the plasma 960	
of mice, increases in tryptophan and other aromatic acid-derived metabolites such as 961	
indole-3-acetic acid, p-cresyl glucuronide, phenyl sulfate and phenylacetic acid were 962	
detected in HP diets (Poesen, et al., 2015).  In the urinary metabolite profile, the HPLC 963	
urinary metabolite profile showed an increase in the fatty acids palmitate and stearate 964	
and a reduction of pantothenate and the TCA cycle intermediates citrate, 2-ketoglutarate 965	
and malate (Mu, et al., 2015). In addition to murine models, study designs in humans 966	
still need to be refined to integrate data from complementary functional omics-967	
technologies to progress in the understanding of the flow of metabolites between the 968	
microbiota and the host derived from dietary protein and their physiological 969	
consequences on the metabolic phenotype.  970	
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 971	
6.  Impact of protein intake levels on health-related outcomes: possible 972	
contribution of gut microbiota metabolic pathways  973	
 Some of the metabolites produced by the microbiota from amino acids have been 974	
shown to be active on numerous host functions as illustrated above. These results 975	
suggest that some of the effects of HP diets on host metabolism and physiology may 976	
involve some of these metabolites and, therefore, microbiota-mediated metabolic 977	
pathways. In the following sections, the effects of high dietary protein intake observed 978	
in human and animal studies are summarized and suggest mechanisms that might 979	
implicate the gut bacteria-derived metabolites (Fig. 6). 980	
 981	
6.1. HP diet-induced satiety  982	
 Two recent meta-analyses of clinical trials concluded that, when compared to 983	
normoproteic (NP) diet, a HP diet modestly reduces body weight, blood pressure, fat 984	
mass and triglyceride levels while sparing fat-free mass (Santesso, et al., 2012; 985	
Wycherley, Moran, Clifton, Noakes, & Brinkworth, 2012). Those effects are mainly 986	
attributed to dietary protein induced satiety (Westerterp-Plantenga, et al., 2009). In 987	
humans, HP diet-induced satiety is associated with an increase of PYY plasma levels 988	
(Batterham, et al., 2006). Implication of gut microbiota in those mechanisms, however, 989	
has not been investigated yet. Nevertheless, SCFAs, indole, tryptamine and tyramine are 990	
compounds produced by the gut microbiota from amino acid precursors and are 991	
candidates for mediating the effects of HP diet on enteroendocrine cell hormone 992	
secretion with an impact on satiety (Figure 6).  993	
 994	
6.2. HP diet effects on the intestinal mucosa 995	
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 In the rat model, HP diet consumption for 15 days resulted in a marked reduction in 996	
the height of the colonocyte brush-border when compared with control animals 997	
receiving a NP/hyperglucidic isocaloric diet (Andriamihaja, et al., 2010). This 998	
morphological change could be related to lower energy efficiency in HP rat colonocytes 999	
due to proton leaks in the mitochondrial inner membrane (Andriamihaja, et al., 2010). A 1000	
reduction of the mucosal myeloperoxidase activity (representative of neutrophil 1001	
infiltration) together with a down-regulation of mucosal Thelper  cytokines was measured 1002	
in the ileum of rats receiving a HP diet (Lan, et al., 2015). This decreased inflammatory 1003	
status was associated with a hyperplasia of mucus-producing cells concomitant with an 1004	
increased expression of Muc2 at both the gene and protein levels (Lan, et al., 2015). A 1005	
HP diet also induced DNA damages in rat colonocytes, in association with an increase 1006	
in the bacterially-derived genotoxic metabolite p-cresol (Toden, Bird, Topping, & 1007	
Conlon, 2005). 1008	
 In an intervention study comparing volunteers receiving either HP diets or low 1009	
protein isocaloric diet for two weeks, no evidence was found for a role of protein 1010	
fermentation in gut toxicity in healthy human subjects despite identification of several 1011	
metabolites in fecal water with presumably cytotoxic and genotoxic effects towards 1012	
colonic epithelial cells (Windey, et al., 2012). SCFA, H2S, p-cresol and ammonia are 1013	
metabolites produced from amino acids that could interfere with colonocyte energy 1014	
metabolism and mucin secretion and may mediate the effects of HP diet on the 1015	
intestinal mucosa. These metabolites could partly result from the activity of gut 1016	
microbiota (Figure 6). However, the consequences of a HP intake on large intestine 1017	
mucosal health have never been directly investigated in humans. 1018	
 1019	
6.2.3. HP diet effects in inflammatory bowel diseases 1020	
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 SCFAs, H2S, indolic compounds, serotonin and histamine are all amino acid-derived 1021	
bacterial metabolites which are likely to interfere with the process of mucosal 1022	
inflammation due to their effects on the mucosal immune response and on the 1023	
maintaining of the epithelial barrier function (Figure 6). As reviewed by Halmos and 1024	
Gibson (2015), only a few studies have examined the impact of the level of protein 1025	
consumption on the risk of inflammatory bowel disease or risk of relapse in diagnosed 1026	
patients. Jowett et al. (2004) reported an increased risk of relapse over 1 year in 1027	
ulcerative colitis patients with the highest meat and protein consumption. A HP diet was 1028	
also associated with an increased risk of incident inflammatory bowel diseases 1029	
(Jantchou, Morois, Clavel-Chapelon, Boutron-Ruault, & Carbonnel, 2010), while Shoda 1030	
et al. (1996) demonstrated that increased consumption of animal protein was related to 1031	
increased incidence of Crohn’s disease. However, another study did not find any 1032	
association between elevated protein intake and development of ulcerative colitis (Hart, 1033	
et al., 2008). 1034	
 1035	
6.2.4. HP diet effects in colorectal cancer 1036	
    Experimental studies with animal models of chemically-induced colonic preneoplasic 1037	
and neoplasic lesions have shown that dietary protein can influence the colonic 1038	
carcinogenesis process, depending on their quantity and quality (McIntosh & Le Leu, 1039	
2001). The production of amino-acid derived genotoxic metabolites produced by the 1040	
microbiota (e.g. p-cresol) could be implicated in this process. However, the complexity 1041	
of the Western diet makes the identification of alimentary compounds that impact the 1042	
risk of colorectal cancer a difficult task. In this context, it has been proposed that the 1043	
positive association between high consumption of red and processed meat and 1044	
colorectal cancer found in some epidemiological studies, may result from both the 1045	
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composition of meat (e.g. heme and protein) and from compounds generated by the 1046	
cooking process (Kim, Coelho, & Blachier, 2013). In support of this hypothesis, a 1047	
recent study has shown that hydrogen sulfide, which is produced by the gut microbiota 1048	
from L-cysteine released from dietary and endogenous protein, can drive mucin 1049	
denaturation and possibly increase the access of heme (a cytotoxic and genotoxic 1050	
compound) to colonic epithelial cells (Ijssennagger, et al., 2015).  1051	
 1052	
6.3. HP diet effects on kidney function  1053	
 It was concluded from a systematic review that indoxyl sulfate and p-cresyl sulfate 1054	
are toxic for kidneys notably through reactive-oxygen species (ROS) generation 1055	
(Vanholder, Schepers, Pletinck, Nagler, & Glorieux, 2014). Moreover, it has been 1056	
proposed that p-cresol level in the blood is an indicator of CKD severity (Bammens, 1057	
Evenepoel, Keuleers, Verbeke, & Vanrenterghem, 2006). Recently, it has been shown 1058	
that CKD alters gut microbiota composition (Vaziri, Wong, et al., 2013) together with 1059	
an increased bacterial metabolic capacity for nitrogen utilization, as evidenced by the 1060	
increased abundance of urease, indole- and p-cresol-forming enzymes in CKD patients 1061	
(Wong, et al., 2014).  Indeed, p-cresyl sulfate (or glucuronide) and indoxyl sulfate are 1062	
known conjugates of the gut microbiota-produced metabolites p-cresol and indole, 1063	
respectively, and are elevated in the serum of chronic kidney diseases (CKD) patients 1064	
(Vanholder & Glorieux, 2015). Furthermore, the elevated uremia in CKD induces an 1065	
important diffusion of urea into the intestinal lumen, and it has been shown that elevated 1066	
urea concentration impairs intestinal barrier function and induces inflammation in the 1067	
digestive tract, most likely through excessive ammonia production by bacterial ureases 1068	
(Vaziri, Yuan, & Norris, 2013), raising the view that CKD may impact gut health. 1069	
Those events may play a causative role in the establishment of CKD-associated 1070	
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dysbiosis. Moreover, CKD patients generally have a lower fiber intake, prolonged 1071	
transit time and protein malabsorption, all of which favor protein fermentation in the gut 1072	
(Evenepoel, et al., 2009). 1073	
 Moderate protein intake (0.6-0.8 g protein/kg/day) has been demonstrated to be 1074	
beneficial for CKD patients (Fouque, Pelletier, Mafra, & Chauveau, 2011). Reduced 1075	
renal exposure to gut microbiota amino acid-derived metabolites through control of 1076	
protein intake may contribute to better health outcomes. In healthy subjects, HP diets 1077	
increase glomerular filtration rate, but the long-term consequences for kidney health 1078	
remains unclear (Marckmann, Osther, Pedersen, & Jespersen, 2015). Thus, renal 1079	
consequences of increased colonic protein fermentation should be further studied in 1080	
healthy subjects. 1081	
 1082	
6.4. Strategies to limit toxicity associated with the control of protein fermentation 1083	
 Increased fermentable carbohydrate intake is one of the nutritional strategies that 1084	
may help to limit adverse effects of protein fermentation, as demonstrated in an 1085	
intervention study which has shown that dietary resistant starch lowers excretion of 1086	
ammonia and phenols (Birkett, et al., 1996). In healthy subjects, p-cresyl sulfate and 1087	
indoxyl sulfate levels are markedly lower in vegetarians than in omnivores, likely 1088	
because of a higher fiber intake and lower protein intake (Patel, Luo, Plummer, 1089	
Hostetter, & Meyer, 2012). In rats, supplementation with resistant starch protects 1090	
against HP diet-induced DNA damages in colonocytes in association with decreased 1091	
excretion of p-cresol (Toden, Belobrajdic, Bird, Topping, & Conlon, 2010). Resistant 1092	
carbohydrate supplementation also attenuates renal injury possibly through a decreased 1093	
production of amino acid-derived metabolites by the microbiota (Vaziri, et al., 2014). In 1094	
CKD patients, improved disease markers (including lower p-cresyl sulfate) were 1095	
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observed after resistant starch supplementation (Vanholder & Glorieux, 2015). 1096	
Unfortunately, CKD patients are advised to restrict their fruit and vegetable intake to 1097	
avoid potassium overload, thus excluding one of the main fiber sources. In that context, 1098	
the use of fibers may be an efficient tool to reduce protein fermentation (De Preter, 1099	
Hamer, Windey, & Verbeke, 2011). This has been demonstrated in human studies with 1100	
isotope-labeled biomarkers showing that fiber (lactulose) efficiently lowered ammonia 1101	
and p-cresol production by the gut microbiota (De Preter, et al., 2004). 1102	
 Consumption of specific probiotic bacteria belonging to the genera Lactobacillus and 1103	
Bifidobacterium has also been shown to decrease urinary p-cresol although to a lesser 1104	
extent than with prebiotics, and with no effect on ammonia (De Preter, et al., 2004; 1105	
Wutzke, Lotz, & Zipprich, 2010). In CKD patients, some probiotic bacteria used to 1106	
reduce the formation of gut-derived toxins have been investigated, but the level of 1107	
evidence remains low (Rossi, et al., 2014). Combining pre- and probiotics (known as 1108	
“synbiotics”) has also been considered an attractive approach, but requires further 1109	
clinical investigation (De Preter, et al., 2007). 1110	
 Other strategies such as elementary nutrition (free amino acid supplementation) or 1111	
the use of substrates that bind deleterious compounds derived from amino-acid 1112	
fermentation (e.g. zinc that binds H2S) have been proposed to minimize their effects in 1113	
medical conditions (e.g. CKD patients) (Mimoun, et al., 2012), but are out of the scope 1114	
of this review.  1115	
 1116	
 1117	
7. Conclusion and perspectives.  1118	
  Dietary protein metabolism is the result of the interplay between host and gut 1119	
bacterial metabolic pathways but their respective roles and contributions to host 1120	
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physiology and metabolic health remain undefined. Several gut microbiota-derived 1121	
amino acid metabolites may theoretically have both beneficial and deleterious 1122	
physiological consequences on host cells and tissues, but so far their effects have only 1123	
been tested individually (i.e. in un-physiological conditions). The use of global-scale 1124	
omics technologies in tightly-controlled intervention studies will help to identify the 1125	
specific gut microbial metabolic pathways activated in response to dietary protein and 1126	
to disentangle the flow of metabolites between the host and the gut microbiota and their 1127	
contribution to host physiology. Moreover, since human diets consist of a wide range of 1128	
different protein sources (plant and animal) with different characteristics (digestibility, 1129	
amino acid composition); these differences also need to be taken into consideration for 1130	
interpretation of metadata obtained in the context of a varied diet. These future studies 1131	
will represent an important and necessary step for a better understanding of the complex 1132	
interplay between diet, microbiota and host metabolism and physiology and will 1133	
contribute to informing microbiome-based dietary recommendations. 1134	
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Figure Captions 1897	
Figure 1: Prokaryotic biosynthetic enzymatic pathways of (A) glutamate and (B) 1898	
serine amino acid families. Enzymes with associated gene names compiled from the 1899	
KEGG database are provided for each step in reaction pathways. Gene names include 1900	
orthologous and paralogous gene groups among different bacterial taxa. Intermediate 1901	
metabolites (yellow boxes) from the most common reaction pathways are provided for 1902	
each end product amino acid (blue boxes) from each enzymatic family. 1903	
 1904	
Figure 2: Prokaryotic biosynthetic enzymatic pathways of the aspartic acid amino 1905	
acid family. Enzymes with associated gene names compiled from the KEGG database 1906	
are provided for each step in reaction pathways. Gene names include orthologous and 1907	
paralogous gene groups among different bacterial taxa. Intermediate metabolites 1908	
(yellow boxes) from the most common reaction pathways are provided for each end 1909	
product amino acid (blue boxes) from each enzymatic family. 1910	
 1911	
Figure 3: Prokaryotic biosynthetic enzymatic pathways of the pyruvate amino acid 1912	
family. Enzymes with associated gene names compiled from the KEGG database are 1913	
provided for each step in reaction pathways. Gene names include orthologous and 1914	
paralogous gene groups among different bacterial taxa. Intermediate metabolites 1915	
(yellow boxes) from the most common reaction pathways are provided for each end 1916	
product amino acid (blue boxes) from each enzymatic family. 1917	
 1918	
Figure 4: Prokaryotic biosynthetic enzymatic pathways of the aromatic acid amino 1919	
acid family. Enzymes with associated gene names compiled from the KEGG database 1920	
are provided for each step in reaction pathways. Gene names include orthologous and 1921	
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paralogous gene groups among different bacterial taxa. Intermediate metabolites 1922	
(yellow boxes) from the most common reaction pathways are provided for each end 1923	
product amino acid (blue boxes) from each enzymatic family. 1924	
 1925	
Figure 5: Prokaryotic biosynthetic enzymatic pathway of histidine. Enzymes with 1926	
associated gene names compiled from the KEGG database are provided for each step in 1927	
reaction pathways. Gene names include orthologous and paralogous gene groups among 1928	
different bacterial taxa. Intermediate metabolites (yellow boxes) from the most common 1929	
reaction pathways are provided for each end product amino acid (blue boxes) from each 1930	
enzymatic family. 1931	
 1932	
Figure 6: High protein diet effects with potential involvement of gut microbiota 1933	
metabolism. Left side: Peptides are degraded by the intestinal microbiota which release 1934	
amino acid derived metabolites in the lumen. Gut bacteria can also produce amino 1935	
acids. Right side: Host-functions affected by a high-protein diet demonstrated in human 1936	
and animal studies (capital letters and bold). High protein diets increase the amount of 1937	
protein available for fermentation by gut microbiota, which may mediate some of the 1938	
effects of high protein diets on host physiology. Candidate bacterial amino acid derived 1939	
metabolites for each effect of high protein diet are proposed. (Illustrations are from 1940	
Servier Medical Art)  1941	
 1942	
Table 1: Gut microbiota-produced metabolites from amino acid catabolism that 1943	
have potential effects on host physiology and health. Genetic pathways for each 1944	
metabolite are described along with enzymes and respective genes for each step in 1945	
metabolic pathways. Gene names identified in the bacterium E. coli are highlighted in 1946	
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bold.  Gene names include orthologous and paralogous gene groups among different 1947	
bacterial taxa. All gene names are compiled from KEGG database except where noted. 1948	
Amino acid abbreviations refer to glutamate (Glu); tryptophan (Tryp); histidine (His); 1949	
tyrosine (Tyr); arginine (Arg); phenylalanine (Phe); cysteine (Cys); methionine (Met); 1950	
lysine (Lys). 1951	
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 Metabolite Amino 
Acid 
Step Substrate(s) Product(s) Enzyme (Enzyme 
Commision Number) 
Gene(s) 
        
Neuroactive compounds  
 GABA Glut 1 L-Glutamate γ-Aminobutanoate, CO2 Glutamate decarboxylase 
(4.1.1.15) 
gadA, gadB 
 Serotonin (5-
hydroxytryptamine) 
Tryp 1 L-Tryptophan, Tetrahydrobiopterin, 
O2 
5-Hydroxy-L-tryptophan, 
Dihydrobiopterin, H2O 
Tryptophan 5-monooxygenase 
(1.14.16.4) 
 
No genes found in 
prokaryotes 
   2 5-Hydroxy-L-tryptophan Serotonin, CO2 Aromatic-L-amino-acid 
decarboxylase (4.1.1.28) 
ddc, dcd, dcd1 
 Histamine (pathway 1) His 1 L-Histidine Histamine, CO2 Histidine decarboxylase 
(4.1.1.22) 
hdc, hdcA, angH, pmsA, 
basG, dchS, vlmD 
 Histamine (pathway 2) His 1 L-Histidine Histamine, CO2 Aromatic-L-amino-acid 
decarboxylase (4.1.1.28) 
ddc, dcd1 
 L-DOPA Tyr 1 L-Tyrosine, O2 3,4-Dihydroxy-L-phenylalanine, 
(DOPA), H2O 
Tyrosinase (1.14.18.1) melO, melC1, melC2 
   2 2 N(ω)-Hydroxyarginine, NADH, H+,  2 Nitric oxide, 2 L-Citrulline, Nitric-oxide synthase nos, nosA, yflM, rplB, 
	 82
O2 NAD+, 2 H2O (1.14.13.165) sdaAB, txtD 
 Tyramine (pathway 1) Tyr 1 L-Tyrosine Tyramine, CO2 Tyrosine decarboxylase 
(4.1.1.25) 
tyrDC, tdcA, mfnA, 
mfmA, gadD, gadB 
 Tyramine (pathway 2) Tyr 1 L-Tyrosine Tyramine, CO2 Aromatic-L-amino-acid 
decarboxylase (4.1.1.28) 
ddc, dcd, dcd1 
 Nitric Oxide Arg 1 L-Arginine, NADH (or NADPH), H+, 
O2 
N(ω)-Hydroxyarginine, NAD+ 
(or NADP+), H2O 
 
Nitric-oxide synthase 
(1.14.13.165) 
nos, nosA, yflM, rplB, 
sdaAB, txtD 
 Tryptamine Tryp 1 L-Tryptophan Tryptamine, CO2 Aromatic-L-amino-acid 
decarboxylase (4.1.1.28) 
dcd, dcd1, ddc 
 Phenylethylamine Phe 1 L-Phenylalanine Phenethylamine, CO2 Aromatic-L-amino-acid 
decarboxylase (4.1.1.28) 
dcd, dcd1, ddc, tyrDC 
        
Sulfide-containing metabolites 
 H2S (pathway 1) Cys 1 L-Cysteine, H2O H2S, Pyruvate, Ammonia Cysteine desulfhydrase 
(4.4.1.1) 
 
cysA, metB, metC, yrhB, 
mccB,  
 H2S (pathway 2) Cys 1 L-Cysteine, H2O H2S, Pyruvate, Ammonia Cystathionine beta-lyase metC, metB, malY, patB 
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(4.4.1.8) 
 Methanethiol Met 1 L-Methionine, H2O Methanethiol, Ammonia, 2-
Oxobutanoate 
Methionine-gamma-lyase 
(4.4.1.11) 
mdeA, megL, metB, metZ 
        
Aromatic compounds 
 Phenol Tyr 1 L-Tyrosine, H2O Phenol, Pyruvate, Ammonia Tyrosine phenol-lyase 
(4.1.99.2) 
tpl 
 p-cresol Tyr 1 L-Tyrosine unknown unknown  Pathway unknown 
(Dawson et al., 2011) 
   2 unknown unknown unknown  
   3 4-hydroxyphenylacetate, H+ 4-methylphenol (p-cresol), CO2 4-hydroxyphenylacetate 
decarboxylase (4.1.1.83) 
hpdB,  hpdC,  hpdA (Yu 
et al., 2006) 
 Indole Tryp 1 L-Tryptophan, H2O Indole, Pyruvate, Ammonia Tryptophanase (4.1.99.1) tnaA 
        
Polyamines 
 Agmatine Arg 1 L-Arginine Agmatine, CO2 Arginine decarboxylase 
(4.1.1.19) 
speA, adiA, cad, pdaD, 
aaxB 
 Putrescine (pathway 1) Arg 1 L-Arginine Agmatine, CO2 Arginine decarboxylase speA, adiA, cad, pdaD, 
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(4.1.1.19) aaxB 
   2 Agmatine, H2O Putrescine, Urea Agmatinase (3.5.3.11) speB, speB1, speB2, pah, 
gbh 
 Putrescine (pathway 2) Arg 1 L-Arginine Agmatine, CO2 Arginine decarboxylase 
(4.1.1.19) 
speA, adiA, cad, pdaD, 
aaxB 
   2 Agmatine, H2O N-Carbamoylputrescine, 
Ammonia 
Agmatine deiminase 
(3.5.3.12) 
aguA, aguA1, aguA2 
   3 N-Carbamoylputrescine, H2O Putrescine, CO2, Ammonia N-carbamoylputrescine 
amidase (3.5.1.53) 
aguB 
 Putrescine (pathway 3) Arg 1 L-Arginine, H2O L-Ornithine, Urea Arginase (3.5.3.1) rocF 
   2 L-Ornithine Putrescine, CO2 Ornithine decarboxylase 
(4.1.1.17) 
speC, speF 
 Spermidine (pathway 1) Arg 1 S-Adenosylmethioninamine, 
putrescine 
5'-Methylthioadenosine, 
Spermidine 
Spermidine synthase 
(2.5.1.16) 
speE 
 Spermidine (pathway 2) Arg 1 L-aspartate 4-semialdehyde, 
putrescine, NADPH, H+ 
carboxyspermidine, H2O, 
NADP+ 
Carboxynorspermidine 
synthase (1.5.1.43) 
cansdh 
   2 carboxyspermidine spermidine, CO2 Carboxynorspermidine 
decarboxylase (4.1.1.96) 
nspC, cansdc 
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1952	
 Spermine Arg 1 S-Adenosylmethioninamine, 
Spermidine 
5'-Methylthioadenosine, 
Spermine 
Spermine synthase (2.5.1.22) SMS (not found in 
prokaryotes) 
        
 Cadaverine Lys 1 L-Lysine Cadaverine, CO2 Lysine decarboxylase 
(4.1.1.18) 
ldcC, cadA, speA, cad 
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 1953	
